IL292262B2 - Formulation of an oral administration form of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid - Google Patents

Formulation of an oral administration form of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid

Info

Publication number
IL292262B2
IL292262B2 IL292262A IL29226222A IL292262B2 IL 292262 B2 IL292262 B2 IL 292262B2 IL 292262 A IL292262 A IL 292262A IL 29226222 A IL29226222 A IL 29226222A IL 292262 B2 IL292262 B2 IL 292262B2
Authority
IL
Israel
Prior art keywords
weight
tablet formulation
compound
granular
component comprises
Prior art date
Application number
IL292262A
Other languages
English (en)
Hebrew (he)
Other versions
IL292262B1 (en
IL292262A (en
Inventor
Alexander Smith
Gurudatt Ajay Chandorkar
Ene Ikpong Ette
Bradley John Maroni
Charlotte Suzanne Hartman
Ramin Farzaneh-Far
Jula Kern Inrig
Original Assignee
Akebia Therapeutics Inc
Alexander Smith
Gurudatt Ajay Chandorkar
Ene Ikpong Ette
Bradley John Maroni
Charlotte Suzanne Hartman
Farzaneh Far Ramin
Jula Kern Inrig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57006457&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL292262(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akebia Therapeutics Inc, Alexander Smith, Gurudatt Ajay Chandorkar, Ene Ikpong Ette, Bradley John Maroni, Charlotte Suzanne Hartman, Farzaneh Far Ramin, Jula Kern Inrig filed Critical Akebia Therapeutics Inc
Publication of IL292262A publication Critical patent/IL292262A/en
Publication of IL292262B1 publication Critical patent/IL292262B1/en
Publication of IL292262B2 publication Critical patent/IL292262B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL292262A 2015-04-01 2016-03-31 Formulation of an oral administration form of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid IL292262B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562141420P 2015-04-01 2015-04-01
US201562270168P 2015-12-21 2015-12-21
PCT/US2016/025235 WO2016161094A1 (en) 2015-04-01 2016-03-31 Compositions and methods for treating anemia

Publications (3)

Publication Number Publication Date
IL292262A IL292262A (en) 2022-06-01
IL292262B1 IL292262B1 (en) 2023-10-01
IL292262B2 true IL292262B2 (en) 2024-02-01

Family

ID=57006457

Family Applications (3)

Application Number Title Priority Date Filing Date
IL305910A IL305910B2 (en) 2015-04-01 2016-03-31 Formulation of an oral dosage form of }]5–(3–chlorophenyl)–3–hydroxypyridine–2–carbonyl[amino{acetic acid
IL292262A IL292262B2 (en) 2015-04-01 2016-03-31 Formulation of an oral administration form of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid
IL254710A IL254710B (en) 2015-04-01 2017-09-26 Oral dosage formulation of {[ 5-(3-(chlorophenyl)- 3-hydroxypyridine-2-carbonyl] amino} acetic acid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL305910A IL305910B2 (en) 2015-04-01 2016-03-31 Formulation of an oral dosage form of }]5–(3–chlorophenyl)–3–hydroxypyridine–2–carbonyl[amino{acetic acid

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL254710A IL254710B (en) 2015-04-01 2017-09-26 Oral dosage formulation of {[ 5-(3-(chlorophenyl)- 3-hydroxypyridine-2-carbonyl] amino} acetic acid

Country Status (35)

Country Link
US (3) US11324734B2 (enExample)
EP (2) EP3277270B1 (enExample)
JP (4) JP6929785B2 (enExample)
KR (3) KR102866021B1 (enExample)
CN (2) CN107645953B (enExample)
AU (3) AU2016243700B2 (enExample)
BR (1) BR112017021097B1 (enExample)
CL (2) CL2017002456A1 (enExample)
CO (1) CO2017011200A2 (enExample)
CR (2) CR20210248A (enExample)
CU (1) CU20170126A7 (enExample)
CY (1) CY1124869T1 (enExample)
DK (1) DK3277270T3 (enExample)
EA (1) EA036920B1 (enExample)
EC (1) ECSP17073209A (enExample)
ES (1) ES2900481T3 (enExample)
HR (1) HRP20211862T1 (enExample)
HU (1) HUE056958T2 (enExample)
IL (3) IL305910B2 (enExample)
LT (1) LT3277270T (enExample)
MA (1) MA41863A (enExample)
MX (3) MX386796B (enExample)
MY (1) MY192705A (enExample)
NZ (1) NZ735973A (enExample)
PE (1) PE20180189A1 (enExample)
PH (1) PH12017501789B1 (enExample)
PL (1) PL3277270T3 (enExample)
PT (1) PT3277270T (enExample)
SA (1) SA517390054B1 (enExample)
SG (1) SG11201707994UA (enExample)
SI (1) SI3277270T1 (enExample)
TW (4) TWI836883B (enExample)
UA (1) UA123308C2 (enExample)
WO (1) WO2016161094A1 (enExample)
ZA (2) ZA201706681B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007265460B2 (en) 2006-06-26 2011-03-03 Akebia Therapeutics Inc. Prolyl hydroxylase inhibitors and methods of use
NO2686520T3 (enExample) 2011-06-06 2018-03-17
MY204336A (en) 2013-06-13 2024-08-23 Akebia Therapeutics Inc Compositions and methods for treating anemia
CN114890943A (zh) 2013-11-15 2022-08-12 阿克比治疗有限公司 {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸固体形式，组合物和用途
AU2016209126A1 (en) 2015-01-23 2017-08-10 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
UA123308C2 (uk) * 2015-04-01 2021-03-17 Екебіа Терапьютікс, Інк. Композиції і способи для лікування анемії
JP6864834B2 (ja) * 2017-06-14 2021-04-28 ニプロ株式会社 投与量決定プログラムおよび投与量決定装置
WO2019028150A1 (en) 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
MX2020011845A (es) 2018-05-09 2021-01-15 Akebia Therapeutics Inc Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico.
CA3159368A1 (en) * 2019-10-31 2021-05-06 Akebia Therapeutics, Inc. Therapeutic methods using vadadustat
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
US20230190731A1 (en) * 2020-03-17 2023-06-22 Zydus Lifesciences Limited Formulation comprising hif prolyl hydroxylase inhibitors
WO2021222424A1 (en) * 2020-04-29 2021-11-04 BioAge Labs, Inc. Hypoxia-inducible factor prolyl hydroxylase inhibitors for treating aging-related conditions
EP4167967A1 (en) * 2020-06-19 2023-04-26 GlaxoSmithKline Intellectual Property (No.2) Limited Formulation comprising daprodustat
WO2021257800A1 (en) 2020-06-19 2021-12-23 Akebia Therapeutics, Inc. Modulation of drug-drug interactions of vadadustat
US20220034871A1 (en) * 2020-07-31 2022-02-03 Daiichi Sankyo Company, Limited Methods for administering pexidartinib
AU2022206302A1 (en) 2021-01-08 2023-08-17 Akebia Therapeutics, Inc. Therapeutic methods using vadadustat
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
AU2022229275A1 (en) 2021-03-01 2023-10-12 Akebia Therapeutics, Inc. Modulation of drug-drug interactions of vadadustat
CN119868550A (zh) * 2023-10-24 2025-04-25 杭州安道药业有限公司 缺氧诱导因子-脯酰胺羟基化酶抑制剂（hif-phi）在罕见贫血中的应用

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655679A (en) 1969-06-25 1972-04-11 Merck & Co Inc Certain aryl pyridine carboxylic acid derivatives
US3703582A (en) 1970-04-20 1972-11-21 Merck & Co Inc Aryl pyridine carboxylic acids in the treatment of inflammation
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
CA1261335A (en) 1984-08-29 1989-09-26 Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee Ethylenediamine monoamide derivatives
CN1023479C (zh) 1985-09-27 1994-01-12 弗·哈夫曼-拉罗切有限公司 乙二胺的单酰胺衍生物的制备方法
TW219933B (enExample) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (de) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
ES2101421T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
EP0650960B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
KR20000065090A (ko) 1996-04-30 2000-11-06 훽스트 악티엔게젤샤프트 3-알콕시피리딘-2-카복실산아미드에스테르,이의제조방법및약제로서의이의용도
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
EP1024134A4 (en) 1997-10-09 2003-05-14 Ono Pharmaceutical Co DERIVATIVES OF AMINOBUTANIC ACID
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
BR9909086A (pt) 1998-03-23 2001-09-04 Aventis Pharm Prod Inc Derivados de piperidinila e n-amidinopiperidinila
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
YU69802A (sh) 2000-03-22 2005-11-28 Pharmacia & Upjohn Company Formulacija oksazolidinon tablete
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
EP1379630B1 (en) 2001-03-21 2012-09-26 Isis Innovation Limited Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
SE0101327D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
US20030176317A1 (en) 2001-12-06 2003-09-18 Volkmar Guenzler-Pukall Stabilization of hypoxia inducible factor (HIF) alpha
CN1668296A (zh) 2002-05-17 2005-09-14 细胞基因公司 使用选择性细胞因子抑制性药物用于治疗和控制癌症和其它疾病的方法及组合物
RU2005108667A (ru) 2002-08-29 2005-08-27 Мерк энд Ко., Инк. (US) Производные n-биарилметиламиноциклоалканкарбоксамида
EP1554394B1 (en) 2002-10-16 2009-12-16 Isis Innovation Limited Screening methods using a structural model of FIH
WO2004048383A1 (en) 2002-11-21 2004-06-10 Eli Lilly And Company Mixed lineage kinase modulators
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
NZ543448A (en) 2003-06-06 2009-02-28 Fibrogen Inc Nitrogen-containing heteroaryl compounds and their use in increasing endogeneous erythropoietin
WO2005007192A2 (en) 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
JPWO2005108370A1 (ja) 2004-04-16 2008-03-21 味の素株式会社 ベンゼン化合物
CA2567619A1 (en) 2004-05-28 2005-12-15 Fibrogen, Inc. Hif prolyl hydroxylase activity assay
JP2008500951A (ja) 2004-05-31 2008-01-17 田辺三菱製薬株式会社 二環化合物
JP2008506702A (ja) 2004-07-14 2008-03-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するための方法
TW200616969A (en) 2004-09-17 2006-06-01 Tanabe Seiyaku Co Imidazole compound
EA014249B1 (ru) * 2005-01-27 2010-10-29 Алембик Лимитед Формуляция леветирацетама длительного высвобождения
WO2006084210A2 (en) 2005-02-04 2006-08-10 Regents Of The University Of California, San Diego Hif modulating compounds and methods of use thereof
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
JP5390184B2 (ja) 2005-06-06 2014-01-15 ファイブローゲン、インコーポレーテッド 貧血の改良された治療方法
CN101242817B (zh) 2005-06-15 2016-08-31 菲布罗根公司 HIF1α调节剂在治疗癌症中的用途
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
WO2007047194A2 (en) 2005-10-11 2007-04-26 Dana-Farber Cancer Institute, Inc. Methods for treating mitf-related disorders
ES2446416T3 (es) 2005-12-09 2014-03-07 Amgen, Inc. Compuestos basados en quinolona que presentan actividad inhibidora de prolil hidroxilasa, composiciones y usos de los mismos
EP1971618A2 (en) 2006-01-09 2008-09-24 Btg International Limited Modulators of hypoxia inducible factor-1 and related uses
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
JP2009523812A (ja) 2006-01-19 2009-06-25 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 融合へテロ二環式キナーゼ阻害剤
JP4801451B2 (ja) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
ITMI20060179A1 (it) 2006-02-02 2007-08-03 Abiogen Pharma Spa Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
WO2007101204A1 (en) 2006-02-27 2007-09-07 Alcon Research, Ltd. Method of treating glaucoma
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
AR059733A1 (es) 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
ES2288117B1 (es) 2006-05-08 2008-12-01 Combino Pharm, S.L. Composicion farmaceutica solida de gabapentina.
WO2007136990A2 (en) 2006-05-16 2007-11-29 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
TWI394747B (zh) 2006-06-23 2013-05-01 Smithkline Beecham Corp 脯胺醯基羥化酶抑制劑
AU2007265460B2 (en) 2006-06-26 2011-03-03 Akebia Therapeutics Inc. Prolyl hydroxylase inhibitors and methods of use
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
JP2008201711A (ja) * 2007-02-20 2008-09-04 Ss Pharmaceut Co Ltd システイン臭が低減された固形製剤
CA2683758A1 (en) 2007-04-18 2008-10-30 Merck & Co., Inc. Novel 1,8-naphthyridine compounds
EP2155680B1 (en) 2007-04-18 2013-12-04 Amgen, Inc Indanone derivatives that inhibit prolyl hydroxylase
CA2685216C (en) 2007-05-04 2014-07-08 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
EP2160187B1 (en) 2007-05-16 2013-05-22 Merck Sharp & Dohme Corp. Spiroindalones
AU2008253311A1 (en) 2007-05-18 2008-11-27 Bayer Schering Pharma Aktiengesellshaft Inhibitors of hypoxia inducible factor (HIF) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
US8268794B2 (en) 2007-08-06 2012-09-18 Senju Pharmaceutical Co., Ltd. Pharmaceutical containing HIF-1 alpha and HIF-2 alpha expression inhibitor
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
KR20100045480A (ko) 2007-08-10 2010-05-03 크리스탈지노믹스(주) 피리딘 유도체 및 이들의 사용방법
WO2009035534A2 (en) 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
WO2009070644A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
JP2011508725A (ja) 2007-11-30 2011-03-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
JP2011507894A (ja) 2007-12-19 2011-03-10 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
WO2009086592A1 (en) 2008-01-04 2009-07-16 Garvan Institute Of Medical Research Method of increasing metabolism
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
KR101208778B1 (ko) 2008-03-03 2012-12-05 노파르티스 아게 Ｔｌｒ 활성 조정제로서의 화합물 및 조성물
KR20110033291A (ko) 2008-07-23 2011-03-30 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물
BRPI0913485A2 (pt) 2008-09-15 2016-06-07 Kasina Laila Innova Pharmaceuticals Private Ltd medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres.
CN105037323A (zh) 2008-11-14 2015-11-11 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
KR101772963B1 (ko) 2009-03-31 2017-08-31 깃세이 야쿠힌 고교 가부시키가이샤 인돌리진 유도체 및 그 의약용도
PH12012500788A1 (en) 2009-11-06 2016-07-27 Aerpio Therapeutics Inc Compositions and methods for treating colitis
AR079343A1 (es) 2009-12-21 2012-01-18 Lilly Co Eli Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico
CN103429239A (zh) 2011-01-13 2013-12-04 菲布罗根有限公司 增加网织红细胞血红蛋白含量的方法
NO2686520T3 (enExample) 2011-06-06 2018-03-17
US8865748B2 (en) 2011-06-06 2014-10-21 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
WO2012174256A2 (en) 2011-06-17 2012-12-20 The Regents Of The University Of Michigan Dna methylation profiles in cancer
JP6099644B2 (ja) 2011-07-22 2017-03-22 ベイジン ベータ ファーマシューティカルズ カンパニー， リミテッド プロリルヒドロキシラーゼ阻害剤としての化合物の多形体、およびその使用
US20140309256A1 (en) 2011-11-09 2014-10-16 Fibrogen, Inc. Therapeutic Method
MX2015006217A (es) 2012-11-19 2015-11-16 Azanta As Tableta dispersable.
CN105492011A (zh) * 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
MX2015016536A (es) * 2013-06-06 2016-08-11 Fibrogen Inc Formulaciones farmacéuticas de un inhibidor de hidroxilasa de hif.
MY204336A (en) * 2013-06-13 2024-08-23 Akebia Therapeutics Inc Compositions and methods for treating anemia
JP2016529257A (ja) 2013-08-16 2016-09-23 オハイオ ステート イノベーション ファウンデーション Ｄｎａメチル化を調節する組成物及び方法
CN114890943A (zh) 2013-11-15 2022-08-12 阿克比治疗有限公司 {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸固体形式，组合物和用途
JP2017503835A (ja) 2014-01-23 2017-02-02 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 眼球疾患治療のための組成物及び方法
US10617716B2 (en) 2014-12-16 2020-04-14 Urgo Us, Inc. Hypochlorous acid formulations and methods for treating skin conditions
AU2016209126A1 (en) 2015-01-23 2017-08-10 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
AU2016235534A1 (en) 2015-03-20 2017-10-12 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
UA123308C2 (uk) 2015-04-01 2021-03-17 Екебіа Терапьютікс, Інк. Композиції і способи для лікування анемії

Also Published As

Publication number Publication date
ZA202006107B (en) 2024-02-28
TW202140001A (zh) 2021-11-01
CY1124869T1 (el) 2022-11-25
MA41863A (fr) 2021-06-02
IL254710B (en) 2022-05-01
CN115607521A (zh) 2023-01-17
SI3277270T1 (sl) 2022-04-29
ES2900481T3 (es) 2022-03-17
HK1248590A1 (zh) 2018-10-19
US20180092892A1 (en) 2018-04-05
CL2017002456A1 (es) 2018-04-20
CO2017011200A2 (es) 2018-04-19
CL2019001927A1 (es) 2019-11-29
AU2020273282A1 (en) 2020-12-17
IL292262B1 (en) 2023-10-01
AU2023200252B2 (en) 2025-03-20
CU20170126A7 (es) 2018-07-05
MX2021012155A (es) 2022-08-02
JP2025069280A (ja) 2025-04-30
JP7629049B2 (ja) 2025-02-12
IL305910B2 (en) 2025-04-01
TW201642839A (zh) 2016-12-16
PH12017501789B1 (en) 2024-02-16
WO2016161094A1 (en) 2016-10-06
JP2018510178A (ja) 2018-04-12
LT3277270T (lt) 2022-01-10
SG11201707994UA (en) 2017-10-30
AU2016243700B2 (en) 2020-08-20
KR20170132865A (ko) 2017-12-04
AU2023200252A1 (en) 2023-02-16
EP3277270B1 (en) 2021-10-27
MX374909B (es) 2025-03-06
MX386796B (es) 2025-03-19
JP2021181478A (ja) 2021-11-25
AU2020273282B2 (en) 2022-10-20
KR20250150155A (ko) 2025-10-17
CN107645953A (zh) 2018-01-30
KR102866021B1 (ko) 2025-09-30
IL292262A (en) 2022-06-01
NZ773901A (en) 2024-07-26
ECSP17073209A (es) 2017-12-01
DK3277270T3 (da) 2021-12-06
TW202421140A (zh) 2024-06-01
US20230071553A1 (en) 2023-03-09
JP7270688B2 (ja) 2023-05-10
IL305910A (en) 2023-11-01
EP3995138A1 (en) 2022-05-11
JP6929785B2 (ja) 2021-09-01
TWI881714B (zh) 2025-04-21
EP3277270A1 (en) 2018-02-07
MY192705A (en) 2022-09-02
NZ735973A (en) 2023-06-30
IL254710A0 (en) 2017-11-30
JP2023093684A (ja) 2023-07-04
CR20210248A (es) 2021-06-01
MX2017012460A (es) 2018-01-30
KR102647879B1 (ko) 2024-03-15
CN107645953B (zh) 2022-11-01
AU2016243700A1 (en) 2017-10-26
UA123308C2 (uk) 2021-03-17
PT3277270T (pt) 2021-12-07
TW202320770A (zh) 2023-06-01
US11844756B2 (en) 2023-12-19
CA2981176A1 (en) 2017-10-06
US11324734B2 (en) 2022-05-10
HUE056958T2 (hu) 2022-04-28
PL3277270T3 (pl) 2022-02-14
KR20240038132A (ko) 2024-03-22
EA201792182A1 (ru) 2018-06-29
PE20180189A1 (es) 2018-01-23
HRP20211862T1 (hr) 2022-03-04
SA517390054B1 (ar) 2022-02-22
CR20170450A (es) 2018-04-03
BR112017021097B1 (pt) 2024-01-02
EA036920B1 (ru) 2021-01-15
US20240325361A1 (en) 2024-10-03
EP3277270A4 (en) 2018-10-31
IL305910B1 (en) 2024-12-01
BR112017021097A2 (pt) 2018-07-03
PH12017501789A1 (en) 2018-04-11
TWI718138B (zh) 2021-02-11
TWI794725B (zh) 2023-03-01
TWI836883B (zh) 2024-03-21
MX2020009415A (es) 2021-10-04
ZA201706681B (en) 2021-02-24

Similar Documents

Publication Publication Date Title
IL292262B2 (en) Formulation of an oral administration form of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid
NZ753904A (en) Compositions and methods for treating anemia
FI3220916T3 (fi) Menetelmä syövän hoitoon n-((4,6-dimetyli-2-okso-1,2-dihydropyridin-3-yyli)metyyli)-5-(etyyli(tetrahydro-2h-pyran-4-yyli)amino)- 4-metyyli-4'-(morfolinometyyli)-[1,1'-bifenyyli]-3-karboksamidilla
IL298998B2 (en) Pharmaceutical formulations of a hif hydroxylase inhibitor
JP2018527392A5 (enExample)
JP2018510178A5 (enExample)
PH12015500313A1 (en) Orally administered medical composition
EP4516353A3 (en) Pharmaceutical compositions comprising (2s)-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
JP2015510916A5 (enExample)
AU2015205188A1 (en) Pharmaceutical preparation containing pyridylamino acetic acid compound
JPWO2009057569A1 (ja) フィルムコーティング製剤
HK1209635A1 (en) Pharmaceutical administration forms comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
AU2019375825A8 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
WO2010029930A1 (ja) 変色が抑制された安定な医薬製剤
WO2006123765A1 (ja) フィルムコーティング製剤
IL276311B1 (en) Methyllactam ring compound and its pharmaceutical use
JP2004538319A5 (enExample)
JP2016512493A5 (enExample)
MX391602B (es) Composicion farmaceutica con antagonista del receptor de mineralocorticoides y su uso
WO2023281089A3 (en) Pharmaceutical composition comprising naproxen and paracetamol
CN102716132B (zh) 复方氨氯地平/缬沙坦/氢氯噻嗪片及其制备方法
WO2006123766A1 (ja) デキストロース含有フィルムコーティング製剤
IL275144B2 (en) Pharmaceutical formulation
JP2016013980A (ja) テルミサルタン含有フィルムコーティング錠剤
RU2422145C2 (ru) Комбинированная противотуберкулезная фармацевтическая композиция